Smith & Nephew plc (LON:SN) has been assigned an average rating of “Hold” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is GBX 1,452.83 ($18.98).
Several analysts have commented on SN shares. Deutsche Bank reiterated a “sell” rating on shares of Smith & Nephew in a research note on Friday, October 5th. UBS Group reiterated a “neutral” rating on shares of Smith & Nephew in a research note on Friday, October 26th. Berenberg Bank increased their target price on Smith & Nephew from GBX 1,370 ($17.90) to GBX 1,475 ($19.27) and gave the company a “hold” rating in a research note on Friday, November 2nd. Finally, HSBC downgraded Smith & Nephew to a “hold” rating and increased their target price for the company from GBX 1,400 ($18.29) to GBX 1,500 ($19.60) in a research note on Tuesday, October 16th.
SN stock opened at GBX 1,442.50 ($18.85) on Monday. Smith & Nephew has a twelve month low of GBX 1,173 ($15.33) and a twelve month high of GBX 1,442 ($18.84).
Smith & Nephew Company Profile
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Further Reading: What is the Rule of 72?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.